Silence Therapeutics (SLNCF) EBITDA Margin (2020 - 2025)
Historic EBITDA Margin for Silence Therapeutics (SLNCF) over the last 6 years, with Q3 2025 value amounting to 16505.66%.
- Silence Therapeutics' EBITDA Margin fell 145509000.0% to 16505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 321.21%, marking a year-over-year increase of 388900.0%. This contributed to the annual value of 146.38% for FY2024, which is 481900.0% up from last year.
- Silence Therapeutics' EBITDA Margin amounted to 16505.66% in Q3 2025, which was down 145509000.0% from 10697.77% recorded in Q2 2025.
- Over the past 5 years, Silence Therapeutics' EBITDA Margin peaked at 0.0% during Q3 2021, and registered a low of 20006.34% during Q1 2025.
- In the last 5 years, Silence Therapeutics' EBITDA Margin had a median value of 386.74% in 2022 and averaged 2932.96%.
- Per our database at Business Quant, Silence Therapeutics' EBITDA Margin skyrocketed by 6163900bps in 2024 and then plummeted by -199727600bps in 2025.
- Silence Therapeutics' EBITDA Margin (Quarter) stood at 329.91% in 2021, then soared by 30bps to 230.03% in 2022, then tumbled by -175bps to 633.59% in 2023, then skyrocketed by 97bps to 17.2% in 2024, then tumbled by -95873bps to 16505.66% in 2025.
- Its last three reported values are 16505.66% in Q3 2025, 10697.77% for Q2 2025, and 20006.34% during Q1 2025.